证券代码：300832 证券简称：新产业 公告编号：2025-043 深圳市新产业生物医学工程股份有限公司 关于获得医疗器械注册证的公告 雄烯二酮（Androstenedione）是一种重要的内源性类固醇激素，属于雄激素 的一员，主要由肾上腺及性腺（女性的卵巢或男性的睾丸）产生。由于雄烯二酮 1 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）收到 了广东省药品监督管理局颁发的 3 项《医疗器械注册证》。具体情况如下： | 序 | 产品名称 | 注册 | 注册证编号 | | | 注册证有效期 | | | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | 分类 | | | | | | | | | | | | | | | | | | | | | | 本试剂盒用于体外定量测 定人血清或血浆中雄烯二 | | | 雄烯二酮测定试 | | 粤械注准 | 2025 | 年 | 0 ...

Group 1 - The number of companies in strategic emerging industries listed on the Shanghai and Shenzhen stock exchanges is approaching 2,700, accounting for over 40% of the market capitalization [1] - More than 90% of new listings on the Sci-Tech Innovation Board, Growth Enterprise Market, and Beijing Stock Exchange in 2024 will belong to strategic emerging industries or high-tech enterprises [1] - The conditions for technology companies to go public have become more accommodating, with multiple listing paths established for unprofitable companies, red-chip companies, and those with special voting rights [1] Group 2 - Since the introduction of the "merger and acquisition six guidelines," listed companies have actively planned mergers and acquisitions, resulting in over 1,400 disclosed asset restructurings, a year-on-year increase of over 40% [1] - The number of major asset restructurings has exceeded 170, showing a year-on-year increase of over 220% [1] - Approximately 650 asset restructurings have been disclosed by companies in strategic emerging industries, with over 80 being major restructurings [1] Group 3 - Since the implementation of the registration system reform, 90% of companies listed on the Sci-Tech Innovation Board and Beijing Stock Exchange, and over half of those on the Growth Enterprise Market, have received investments from private equity and venture capital funds [2] - The scale and proportion of investments from private equity and venture capital funds in strategic emerging industries continue to rise, with over 100,000 projects currently funded and total investment exceeding 4 trillion yuan [2] - The bond market has become an important channel for direct financing for technology companies, with cumulative issuance of Sci-Tech bonds reaching 1.2 trillion yuan [2] Group 4 - In 2024, 539 Sci-Tech bonds were issued, with a total issuance scale of 610 billion yuan, representing a year-on-year increase of 64% [2] - The funds raised are primarily directed towards cutting-edge fields such as semiconductors, artificial intelligence, new energy, and high-end manufacturing [2]

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a decline of 1.26% recently, reflecting broader market trends in the healthcare sector [1]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services closed at 13,370.1 points with a trading volume of 11.048 billion yuan [1]. - Over the past month, the index has increased by 2.41%, but it has decreased by 7.73% over the last three months and is down 1.09% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, selected from the broader China Securities Index to reflect the overall performance of healthcare-related securities [1]. - The top ten weighted companies in the index include Mindray Medical (9.6%), Aier Eye Hospital (8.13%), and United Imaging Healthcare (7.77%) among others [1]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.46%) and the Shanghai Stock Exchange (39.54%) [1]. Group 3: Fund Tracking - Several public funds track the China Securities Index for Healthcare Equipment and Services, including Southern China Securities Index Healthcare Equipment and Services Link A, and Tianhong China Securities Index Healthcare Equipment and Services ETF [2].

Core Insights - XCMG Group has successfully hosted the International Customer Festival for seven consecutive years, which serves as a global marketing accelerator and a foundation for advanced manufacturing in Xuzhou [1][2] - The company has achieved over 100 billion yuan in operating scale for five consecutive years, with international revenue accounting for more than 46% [2] - XCMG Group aims to double its scale to over 200 billion yuan by 2030, with international revenue expected to exceed 60% [2] Group 1 - The International Customer Festival attracted over 2,000 guests from more than 80 countries, showcasing XCMG's advantages in the engineering machinery industry [1] - XCMG's product range includes construction machinery, commercial vehicles, mining machinery, agricultural machinery, sanitation equipment, emergency rescue gear, and core components [1] - The company focuses on a "5+1" industrial layout, strengthening its core engineering machinery sector while developing strategic new industries and upgrading modern services [1] Group 2 - XCMG has established a global operational system of "1+14+N," with R&D centers in countries such as Germany, the USA, Australia, and Brazil [2] - The company has developed a range of green and intelligent products, including the world's largest hybrid all-terrain crane and fully electric loaders [2] - XCMG's future strategy emphasizes transitioning from a traditional manufacturing company to a solution-oriented service provider, enhancing global integration and operational efficiency [2]

证券代码：300832 证券简称：新产业 公告编号：2025-042 深圳市新产业生物医学工程股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）2024 年年 度权益分派方案已获 2025 年 5 月 19 日召开的 2024 年年度股东会审议通过，现 将权益分派具体实施事宜公告如下： 一、 股东会审议通过的权益分配方案情况 1. 2024 年年度股东会审议通过的分配方案为：以 2024 年年度权益分派实 施公告中确定的股权登记日下午收市时的总股本为基数，按每股分配现金红利金 额不变的原则，向全体股东每 10 股派发现金红利 13 元（含税），不送红股，不 以资本公积金转增股本。 2. 本次实施的权益分派方案与 2024 年年度股东会审议通过的分配方案及 其调整原则一致。 3. 本次实施的权益分派方案距离股东会审议通过时间未超过两个月。 二、 本次实施的权益分派方案 本公司 2024 年年度权益分派方案为：以公司现有总股本 785,718,785 股为基 数， ...

Group 1 - The core viewpoint of the news is the performance and structure of the China Europe CSI All-Share Healthcare Equipment and Services Index Fund A, which has experienced a slight decline recently [1] - As of May 19, the fund's latest net value is 1.05 yuan, marking a continuous drop for four trading days with a cumulative decline of 1.26% [1] - The fund was established in August 2024 with a total size of 0.13 billion yuan and has achieved a cumulative return of 4.82% since inception [1] Group 2 - The fund's holder structure shows that institutional investors hold 0.10 billion shares, accounting for 91.94% of the total shares, while individual investors hold 0.01 billion shares, making up 8.06% [1] - As of March 31, 2025, the top ten holdings of the fund account for a total of 41.48%, with major investments in companies such as Mindray Medical (9.10%), Aier Eye Hospital (7.77%), and United Imaging Healthcare (6.36%) [3]

Group 1 - The core point of the news is the performance and structure of the Huatai-PineBridge CSI Information Technology Application Innovation Industry ETF Initiation Link A, which has seen a decline in its net value and cumulative returns since its establishment [1] - As of May 19, the fund's net value is 1.33 yuan, with a decline of 0.02% on that day and a cumulative drop of 3.54% over three trading days [1] - The fund was established in June 2024 with a total size of 0.45 billion yuan and has achieved a cumulative return of 32.69% since inception [1] Group 2 - The fund's holder structure shows that institutional investors hold 0.10 billion shares, accounting for 54.98% of the total shares, while individual investors hold 0.08 billion shares, making up 45.02% [1] - The current fund manager, Sun Hao, has a background in finance with a master's degree from Peking University and has been managing multiple funds since August 2023 [2] - As of March 31, 2025, the top two holdings of the fund account for a combined 0.14%, both being 23 government bonds [3]

深圳市福田区中心五路 18 号星河中心大厦 19 层 电话：0755-23993388 传真：0755-86186205 邮编：518048 北京国枫（深圳）律师事务所 关于深圳市新产业生物医学工程股份有限公司 2024 年年度股东会的 法律意见书 国枫律股字[2025]C0047 号 致：深圳市新产业生物医学工程股份有限公司（贵公司） 北京国枫（深圳）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2024 年年度股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）、《上市公司股东会规则》（以下简称《股东会规 则》）、《律师事务所从事证券法律业务管理办法》（以下简称《证券法律业务管理办法》）、 《律师事务所证券法律业务执业规则（试行）》（以下简称《证券法律业务执业规则》）等 相关法律、行政法规、规章、规范性文件及《深圳市新产业生物医学工程股份有限公司 章程》（以下简称《公司章程》）的规定，就本次会议的召集与召开程序、召集人资格、 出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见 ...

2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）本次股东会的召开情况 1、会议召集人：深圳市新产业生物医学工程股份有限公司第五届董事会 证券代码：300832 证券简称：新产业 公告编号：2025-041 深圳市新产业生物医学工程股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； （二）会议出席情况 出席本次股东会现场会议投票和网络投票的股东及股东授权委托代表共 317名，代表有表决权股份521,799,535股，占公司有表决权股份总数的66.4105%。 其中，通过现场投票的股东及股东授权委托代表 14 名，代表有表决权股份 114,452,810 股，占公司有表决权股份总数的 14.5666%；通过网络投票的股东 303 名，代表有表决权股份 407,346,725 股，占公司有表决权股份总数的 51.8438%。 出席本次股东会现场会议投票和网络投票的中小股东及股东授权委托代表 共 310 名，代表有表决权股份 82,084,485 ...

Economic Growth and Achievements - The "14th Five-Year Plan" has seen 99% of its 102 major projects and over 5,000 specific projects completed ahead of schedule [1] - China's GDP reached 134.91 trillion yuan in 2024, an increase of 31.42 trillion yuan from 2020, with an expected economic increment exceeding 30 trillion yuan during the "14th Five-Year Plan" [3] - The average GDP growth rates from 2021 to 2024 were 8.6%, 3.1%, 5.4%, and 5.0%, consistently higher than the global average [2] Industrial Development - The modern industrial system has made significant progress, with the primary industry maintaining steady growth and the secondary and tertiary industries contributing the most to GDP [4] - The added value of the equipment manufacturing and high-tech manufacturing industries grew by 7.7% and 8.9% respectively in 2024, surpassing the overall industrial growth rates [4] Emerging Industries - The "Three New" economy (new industries, new business formats, and new models) accounted for over 18% of GDP in 2024, with China leading globally in several sectors, including electric vehicles and renewable energy installations [5][6] - The digital economy's core industries contributed approximately 10% to GDP, achieving the targets set in the "14th Five-Year Plan" ahead of schedule [5][6] Trade and Export Performance - In 2024, China's total goods import and export volume reached 43.85 trillion yuan, marking a historical high and maintaining its position as the world's largest goods trader for eight consecutive years [7] - The export of mechanical and electrical products amounted to 15.12 trillion yuan in 2024, accounting for 59.43% of total exports, with significant growth in high-end equipment exports [7] - Cross-border e-commerce saw explosive growth, with imports and exports reaching 2.63 trillion yuan in 2024, a 55% increase from 2020 [8] Regional Trade Dynamics - ASEAN has become China's largest trading partner, with a trade surplus of 190.71 billion USD in 2024, reflecting a shift in trade dynamics and alignment with the "14th Five-Year Plan" goals [8]